Two pharma companies barred from manufacturing unapproved drugs
Pharma Compliance Alert, April 15, 2009
The FDA barred Neilgen Pharmaceuticals and its parent company, Advent Pharmaceuticals from manufacturing or distributing unapproved drugs, according to an agency release.
Neilgen and Advent manufacture and distribute more than 25 different unapproved drug products each. Most are prescription cough and cold products. Because these products have not gone through FDA testing, their safety and effectiveness is unknown. In addition, the FDA has not reviewed the adequacy and accuracy of the directions for use and warnings on the labeling.
Read more about the FDA's action against Advent and Neilgen
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Case Management Monthly, March 2012
- Searched
